line_item,period,value,symbol
Tax Effect Of Unusual Items,2025-03-31 00:00:00,0.0,CYIENTDLM.NS
Tax Rate For Calcs,2025-03-31 00:00:00,0.257817,CYIENTDLM.NS
Normalized EBITDA,2025-03-31 00:00:00,1633310000.0,CYIENTDLM.NS
Total Unusual Items,2025-03-31 00:00:00,,CYIENTDLM.NS
Total Unusual Items Excluding Goodwill,2025-03-31 00:00:00,,CYIENTDLM.NS
Net Income From Continuing Operation Net Minority Interest,2025-03-31 00:00:00,680760000.0,CYIENTDLM.NS
Reconciled Depreciation,2025-03-31 00:00:00,340620000.0,CYIENTDLM.NS
Reconciled Cost Of Revenue,2025-03-31 00:00:00,11081940000.0,CYIENTDLM.NS
EBITDA,2025-03-31 00:00:00,1633310000.0,CYIENTDLM.NS
EBIT,2025-03-31 00:00:00,1292690000.0,CYIENTDLM.NS
Net Interest Income,2025-03-31 00:00:00,-375450000.0,CYIENTDLM.NS
Interest Expense,2025-03-31 00:00:00,375450000.0,CYIENTDLM.NS
Interest Income,2025-03-31 00:00:00,,CYIENTDLM.NS
Normalized Income,2025-03-31 00:00:00,680760000.0,CYIENTDLM.NS
Net Income From Continuing And Discontinued Operation,2025-03-31 00:00:00,680760000.0,CYIENTDLM.NS
Total Expenses,2025-03-31 00:00:00,14165140000.0,CYIENTDLM.NS
Diluted Average Shares,2025-03-31 00:00:00,79528037.0,CYIENTDLM.NS
Basic Average Shares,2025-03-31 00:00:00,79342657.0,CYIENTDLM.NS
Diluted EPS,2025-03-31 00:00:00,8.56,CYIENTDLM.NS
Basic EPS,2025-03-31 00:00:00,8.58,CYIENTDLM.NS
Diluted NI Availto Com Stockholders,2025-03-31 00:00:00,680760000.0,CYIENTDLM.NS
Net Income Common Stockholders,2025-03-31 00:00:00,680760000.0,CYIENTDLM.NS
Otherunder Preferred Stock Dividend,2025-03-31 00:00:00,0.0,CYIENTDLM.NS
Net Income,2025-03-31 00:00:00,680760000.0,CYIENTDLM.NS
Net Income Including Noncontrolling Interests,2025-03-31 00:00:00,680760000.0,CYIENTDLM.NS
Net Income Continuous Operations,2025-03-31 00:00:00,680760000.0,CYIENTDLM.NS
Tax Provision,2025-03-31 00:00:00,236480000.0,CYIENTDLM.NS
Pretax Income,2025-03-31 00:00:00,917240000.0,CYIENTDLM.NS
Other Non Operating Income Expenses,2025-03-31 00:00:00,287580000.0,CYIENTDLM.NS
Special Income Charges,2025-03-31 00:00:00,,CYIENTDLM.NS
Other Special Charges,2025-03-31 00:00:00,,CYIENTDLM.NS
Write Off,2025-03-31 00:00:00,,CYIENTDLM.NS
Net Non Operating Interest Income Expense,2025-03-31 00:00:00,-375450000.0,CYIENTDLM.NS
Total Other Finance Cost,2025-03-31 00:00:00,,CYIENTDLM.NS
Interest Expense Non Operating,2025-03-31 00:00:00,375450000.0,CYIENTDLM.NS
Interest Income Non Operating,2025-03-31 00:00:00,,CYIENTDLM.NS
Operating Income,2025-03-31 00:00:00,1031120000.0,CYIENTDLM.NS
Operating Expense,2025-03-31 00:00:00,3083200000.0,CYIENTDLM.NS
Other Operating Expenses,2025-03-31 00:00:00,880400000.0,CYIENTDLM.NS
Depreciation And Amortization In Income Statement,2025-03-31 00:00:00,340620000.0,CYIENTDLM.NS
Amortization,2025-03-31 00:00:00,,CYIENTDLM.NS
Depreciation Income Statement,2025-03-31 00:00:00,340620000.0,CYIENTDLM.NS
Research And Development,2025-03-31 00:00:00,,CYIENTDLM.NS
Selling General And Administration,2025-03-31 00:00:00,,CYIENTDLM.NS
Selling And Marketing Expense,2025-03-31 00:00:00,,CYIENTDLM.NS
General And Administrative Expense,2025-03-31 00:00:00,,CYIENTDLM.NS
Gross Profit,2025-03-31 00:00:00,4114320000.0,CYIENTDLM.NS
Cost Of Revenue,2025-03-31 00:00:00,11081940000.0,CYIENTDLM.NS
Total Revenue,2025-03-31 00:00:00,15196260000.0,CYIENTDLM.NS
Operating Revenue,2025-03-31 00:00:00,15196260000.0,CYIENTDLM.NS
Tax Effect Of Unusual Items,2024-03-31 00:00:00,0.0,CYIENTDLM.NS
Tax Rate For Calcs,2024-03-31 00:00:00,0.25497,CYIENTDLM.NS
Normalized EBITDA,2024-03-31 00:00:00,1388380000.0,CYIENTDLM.NS
Total Unusual Items,2024-03-31 00:00:00,0.0,CYIENTDLM.NS
Total Unusual Items Excluding Goodwill,2024-03-31 00:00:00,0.0,CYIENTDLM.NS
Net Income From Continuing Operation Net Minority Interest,2024-03-31 00:00:00,611960000.0,CYIENTDLM.NS
Reconciled Depreciation,2024-03-31 00:00:00,223120000.0,CYIENTDLM.NS
Reconciled Cost Of Revenue,2024-03-31 00:00:00,9199600000.0,CYIENTDLM.NS
EBITDA,2024-03-31 00:00:00,1388380000.0,CYIENTDLM.NS
EBIT,2024-03-31 00:00:00,1165260000.0,CYIENTDLM.NS
Net Interest Income,2024-03-31 00:00:00,-343870000.0,CYIENTDLM.NS
Interest Expense,2024-03-31 00:00:00,343870000.0,CYIENTDLM.NS
Interest Income,2024-03-31 00:00:00,274940000.0,CYIENTDLM.NS
Normalized Income,2024-03-31 00:00:00,611960000.0,CYIENTDLM.NS
Net Income From Continuing And Discontinued Operation,2024-03-31 00:00:00,611960000.0,CYIENTDLM.NS
Total Expenses,2024-03-31 00:00:00,11031710000.0,CYIENTDLM.NS
Diluted Average Shares,2024-03-31 00:00:00,72939213.0,CYIENTDLM.NS
Basic Average Shares,2024-03-31 00:00:00,72679335.0,CYIENTDLM.NS
Diluted EPS,2024-03-31 00:00:00,8.39,CYIENTDLM.NS
Basic EPS,2024-03-31 00:00:00,8.42,CYIENTDLM.NS
Diluted NI Availto Com Stockholders,2024-03-31 00:00:00,611960000.0,CYIENTDLM.NS
Net Income Common Stockholders,2024-03-31 00:00:00,611960000.0,CYIENTDLM.NS
Otherunder Preferred Stock Dividend,2024-03-31 00:00:00,0.0,CYIENTDLM.NS
Net Income,2024-03-31 00:00:00,611960000.0,CYIENTDLM.NS
Net Income Including Noncontrolling Interests,2024-03-31 00:00:00,611960000.0,CYIENTDLM.NS
Net Income Continuous Operations,2024-03-31 00:00:00,611960000.0,CYIENTDLM.NS
Tax Provision,2024-03-31 00:00:00,209430000.0,CYIENTDLM.NS
Pretax Income,2024-03-31 00:00:00,821390000.0,CYIENTDLM.NS
Other Non Operating Income Expenses,2024-03-31 00:00:00,314420000.0,CYIENTDLM.NS
Special Income Charges,2024-03-31 00:00:00,0.0,CYIENTDLM.NS
Other Special Charges,2024-03-31 00:00:00,,CYIENTDLM.NS
Write Off,2024-03-31 00:00:00,,CYIENTDLM.NS
Net Non Operating Interest Income Expense,2024-03-31 00:00:00,-343870000.0,CYIENTDLM.NS
Total Other Finance Cost,2024-03-31 00:00:00,14090000.0,CYIENTDLM.NS
Interest Expense Non Operating,2024-03-31 00:00:00,343870000.0,CYIENTDLM.NS
Interest Income Non Operating,2024-03-31 00:00:00,274940000.0,CYIENTDLM.NS
Operating Income,2024-03-31 00:00:00,887000000.0,CYIENTDLM.NS
Operating Expense,2024-03-31 00:00:00,1832110000.0,CYIENTDLM.NS
Other Operating Expenses,2024-03-31 00:00:00,435190000.0,CYIENTDLM.NS
Depreciation And Amortization In Income Statement,2024-03-31 00:00:00,223120000.0,CYIENTDLM.NS
Amortization,2024-03-31 00:00:00,16450000.0,CYIENTDLM.NS
Depreciation Income Statement,2024-03-31 00:00:00,223120000.0,CYIENTDLM.NS
Research And Development,2024-03-31 00:00:00,2870000.0,CYIENTDLM.NS
Selling General And Administration,2024-03-31 00:00:00,141480000.0,CYIENTDLM.NS
Selling And Marketing Expense,2024-03-31 00:00:00,73530000.0,CYIENTDLM.NS
General And Administrative Expense,2024-03-31 00:00:00,67950000.0,CYIENTDLM.NS
Gross Profit,2024-03-31 00:00:00,2719110000.0,CYIENTDLM.NS
Cost Of Revenue,2024-03-31 00:00:00,9199600000.0,CYIENTDLM.NS
Total Revenue,2024-03-31 00:00:00,11918710000.0,CYIENTDLM.NS
Operating Revenue,2024-03-31 00:00:00,11918710000.0,CYIENTDLM.NS
Tax Effect Of Unusual Items,2023-03-31 00:00:00,-1472833.178869,CYIENTDLM.NS
Tax Rate For Calcs,2023-03-31 00:00:00,0.264898,CYIENTDLM.NS
Normalized EBITDA,2023-03-31 00:00:00,927900000.0,CYIENTDLM.NS
Total Unusual Items,2023-03-31 00:00:00,-5560000.0,CYIENTDLM.NS
Total Unusual Items Excluding Goodwill,2023-03-31 00:00:00,-5560000.0,CYIENTDLM.NS
Net Income From Continuing Operation Net Minority Interest,2023-03-31 00:00:00,317270000.0,CYIENTDLM.NS
Reconciled Depreciation,2023-03-31 00:00:00,194150000.0,CYIENTDLM.NS
Reconciled Cost Of Revenue,2023-03-31 00:00:00,6452140000.0,CYIENTDLM.NS
EBITDA,2023-03-31 00:00:00,922340000.0,CYIENTDLM.NS
EBIT,2023-03-31 00:00:00,728190000.0,CYIENTDLM.NS
Net Interest Income,2023-03-31 00:00:00,-285150000.0,CYIENTDLM.NS
Interest Expense,2023-03-31 00:00:00,296590000.0,CYIENTDLM.NS
Interest Income,2023-03-31 00:00:00,30010000.0,CYIENTDLM.NS
Normalized Income,2023-03-31 00:00:00,321357166.821131,CYIENTDLM.NS
Net Income From Continuing And Discontinued Operation,2023-03-31 00:00:00,317270000.0,CYIENTDLM.NS
Total Expenses,2023-03-31 00:00:00,7633050000.0,CYIENTDLM.NS
Diluted Average Shares,2023-03-31 00:00:00,79306124.0,CYIENTDLM.NS
Basic Average Shares,2023-03-31 00:00:00,79306124.0,CYIENTDLM.NS
Diluted EPS,2023-03-31 00:00:00,4.000574,CYIENTDLM.NS
Basic EPS,2023-03-31 00:00:00,4.000574,CYIENTDLM.NS
Diluted NI Availto Com Stockholders,2023-03-31 00:00:00,317270000.0,CYIENTDLM.NS
Net Income Common Stockholders,2023-03-31 00:00:00,317270000.0,CYIENTDLM.NS
Otherunder Preferred Stock Dividend,2023-03-31 00:00:00,0.0,CYIENTDLM.NS
Net Income,2023-03-31 00:00:00,317270000.0,CYIENTDLM.NS
Net Income Including Noncontrolling Interests,2023-03-31 00:00:00,317270000.0,CYIENTDLM.NS
Net Income Continuous Operations,2023-03-31 00:00:00,317270000.0,CYIENTDLM.NS
Tax Provision,2023-03-31 00:00:00,114330000.0,CYIENTDLM.NS
Pretax Income,2023-03-31 00:00:00,431600000.0,CYIENTDLM.NS
Other Non Operating Income Expenses,2023-03-31 00:00:00,7410000.0,CYIENTDLM.NS
Special Income Charges,2023-03-31 00:00:00,-5560000.0,CYIENTDLM.NS
Other Special Charges,2023-03-31 00:00:00,5560000.0,CYIENTDLM.NS
Write Off,2023-03-31 00:00:00,0.0,CYIENTDLM.NS
Net Non Operating Interest Income Expense,2023-03-31 00:00:00,-285150000.0,CYIENTDLM.NS
Total Other Finance Cost,2023-03-31 00:00:00,18570000.0,CYIENTDLM.NS
Interest Expense Non Operating,2023-03-31 00:00:00,296590000.0,CYIENTDLM.NS
Interest Income Non Operating,2023-03-31 00:00:00,30010000.0,CYIENTDLM.NS
Operating Income,2023-03-31 00:00:00,687280000.0,CYIENTDLM.NS
Operating Expense,2023-03-31 00:00:00,1180910000.0,CYIENTDLM.NS
Other Operating Expenses,2023-03-31 00:00:00,227290000.0,CYIENTDLM.NS
Depreciation And Amortization In Income Statement,2023-03-31 00:00:00,194150000.0,CYIENTDLM.NS
Amortization,2023-03-31 00:00:00,9780000.0,CYIENTDLM.NS
Depreciation Income Statement,2023-03-31 00:00:00,184370000.0,CYIENTDLM.NS
Research And Development,2023-03-31 00:00:00,1570000.0,CYIENTDLM.NS
Selling General And Administration,2023-03-31 00:00:00,114590000.0,CYIENTDLM.NS
Selling And Marketing Expense,2023-03-31 00:00:00,73690000.0,CYIENTDLM.NS
General And Administrative Expense,2023-03-31 00:00:00,40900000.0,CYIENTDLM.NS
Gross Profit,2023-03-31 00:00:00,1868190000.0,CYIENTDLM.NS
Cost Of Revenue,2023-03-31 00:00:00,6452140000.0,CYIENTDLM.NS
Total Revenue,2023-03-31 00:00:00,8320330000.0,CYIENTDLM.NS
Operating Revenue,2023-03-31 00:00:00,8320330000.0,CYIENTDLM.NS
Tax Effect Of Unusual Items,2022-03-31 00:00:00,954899.467771,CYIENTDLM.NS
Tax Rate For Calcs,2022-03-31 00:00:00,0.215553,CYIENTDLM.NS
Normalized EBITDA,2022-03-31 00:00:00,886340000.0,CYIENTDLM.NS
Total Unusual Items,2022-03-31 00:00:00,4430000.0,CYIENTDLM.NS
Total Unusual Items Excluding Goodwill,2022-03-31 00:00:00,4430000.0,CYIENTDLM.NS
Net Income From Continuing Operation Net Minority Interest,2022-03-31 00:00:00,397950000.0,CYIENTDLM.NS
Reconciled Depreciation,2022-03-31 00:00:00,192860000.0,CYIENTDLM.NS
Reconciled Cost Of Revenue,2022-03-31 00:00:00,5439620000.0,CYIENTDLM.NS
EBITDA,2022-03-31 00:00:00,890770000.0,CYIENTDLM.NS
EBIT,2022-03-31 00:00:00,697910000.0,CYIENTDLM.NS
Net Interest Income,2022-03-31 00:00:00,-203660000.0,CYIENTDLM.NS
Interest Expense,2022-03-31 00:00:00,190610000.0,CYIENTDLM.NS
Interest Income,2022-03-31 00:00:00,16090000.0,CYIENTDLM.NS
Normalized Income,2022-03-31 00:00:00,394474899.467771,CYIENTDLM.NS
Net Income From Continuing And Discontinued Operation,2022-03-31 00:00:00,397950000.0,CYIENTDLM.NS
Total Expenses,2022-03-31 00:00:00,6499360000.0,CYIENTDLM.NS
Diluted Average Shares,2022-03-31 00:00:00,79315055.0,CYIENTDLM.NS
Basic Average Shares,2022-03-31 00:00:00,79315055.0,CYIENTDLM.NS
Diluted EPS,2022-03-31 00:00:00,5.017332,CYIENTDLM.NS
Basic EPS,2022-03-31 00:00:00,5.017332,CYIENTDLM.NS
Diluted NI Availto Com Stockholders,2022-03-31 00:00:00,397950000.0,CYIENTDLM.NS
Net Income Common Stockholders,2022-03-31 00:00:00,397950000.0,CYIENTDLM.NS
Otherunder Preferred Stock Dividend,2022-03-31 00:00:00,0.0,CYIENTDLM.NS
Net Income,2022-03-31 00:00:00,397950000.0,CYIENTDLM.NS
Net Income Including Noncontrolling Interests,2022-03-31 00:00:00,397950000.0,CYIENTDLM.NS
Net Income Continuous Operations,2022-03-31 00:00:00,397950000.0,CYIENTDLM.NS
Tax Provision,2022-03-31 00:00:00,109350000.0,CYIENTDLM.NS
Pretax Income,2022-03-31 00:00:00,507300000.0,CYIENTDLM.NS
Other Non Operating Income Expenses,2022-03-31 00:00:00,330000.0,CYIENTDLM.NS
Special Income Charges,2022-03-31 00:00:00,4430000.0,CYIENTDLM.NS
Other Special Charges,2022-03-31 00:00:00,-940000.0,CYIENTDLM.NS
Write Off,2022-03-31 00:00:00,-3490000.0,CYIENTDLM.NS
Net Non Operating Interest Income Expense,2022-03-31 00:00:00,-203660000.0,CYIENTDLM.NS
Total Other Finance Cost,2022-03-31 00:00:00,29140000.0,CYIENTDLM.NS
Interest Expense Non Operating,2022-03-31 00:00:00,190610000.0,CYIENTDLM.NS
Interest Income Non Operating,2022-03-31 00:00:00,16090000.0,CYIENTDLM.NS
Operating Income,2022-03-31 00:00:00,705970000.0,CYIENTDLM.NS
Operating Expense,2022-03-31 00:00:00,1059740000.0,CYIENTDLM.NS
Other Operating Expenses,2022-03-31 00:00:00,139830000.0,CYIENTDLM.NS
Depreciation And Amortization In Income Statement,2022-03-31 00:00:00,192860000.0,CYIENTDLM.NS
Amortization,2022-03-31 00:00:00,6970000.0,CYIENTDLM.NS
Depreciation Income Statement,2022-03-31 00:00:00,185890000.0,CYIENTDLM.NS
Research And Development,2022-03-31 00:00:00,2880000.0,CYIENTDLM.NS
Selling General And Administration,2022-03-31 00:00:00,252930000.0,CYIENTDLM.NS
Selling And Marketing Expense,2022-03-31 00:00:00,202120000.0,CYIENTDLM.NS
General And Administrative Expense,2022-03-31 00:00:00,50810000.0,CYIENTDLM.NS
Gross Profit,2022-03-31 00:00:00,1765710000.0,CYIENTDLM.NS
Cost Of Revenue,2022-03-31 00:00:00,5439620000.0,CYIENTDLM.NS
Total Revenue,2022-03-31 00:00:00,7205330000.0,CYIENTDLM.NS
Operating Revenue,2022-03-31 00:00:00,7205330000.0,CYIENTDLM.NS
Tax Effect Of Unusual Items,2021-03-31 00:00:00,,CYIENTDLM.NS
Tax Rate For Calcs,2021-03-31 00:00:00,,CYIENTDLM.NS
Normalized EBITDA,2021-03-31 00:00:00,,CYIENTDLM.NS
Total Unusual Items,2021-03-31 00:00:00,0.0,CYIENTDLM.NS
Total Unusual Items Excluding Goodwill,2021-03-31 00:00:00,0.0,CYIENTDLM.NS
Net Income From Continuing Operation Net Minority Interest,2021-03-31 00:00:00,,CYIENTDLM.NS
Reconciled Depreciation,2021-03-31 00:00:00,,CYIENTDLM.NS
Reconciled Cost Of Revenue,2021-03-31 00:00:00,,CYIENTDLM.NS
EBITDA,2021-03-31 00:00:00,,CYIENTDLM.NS
EBIT,2021-03-31 00:00:00,,CYIENTDLM.NS
Net Interest Income,2021-03-31 00:00:00,,CYIENTDLM.NS
Interest Expense,2021-03-31 00:00:00,,CYIENTDLM.NS
Interest Income,2021-03-31 00:00:00,17590000.0,CYIENTDLM.NS
Normalized Income,2021-03-31 00:00:00,,CYIENTDLM.NS
Net Income From Continuing And Discontinued Operation,2021-03-31 00:00:00,,CYIENTDLM.NS
Total Expenses,2021-03-31 00:00:00,,CYIENTDLM.NS
Diluted Average Shares,2021-03-31 00:00:00,,CYIENTDLM.NS
Basic Average Shares,2021-03-31 00:00:00,,CYIENTDLM.NS
Diluted EPS,2021-03-31 00:00:00,,CYIENTDLM.NS
Basic EPS,2021-03-31 00:00:00,,CYIENTDLM.NS
Diluted NI Availto Com Stockholders,2021-03-31 00:00:00,,CYIENTDLM.NS
Net Income Common Stockholders,2021-03-31 00:00:00,,CYIENTDLM.NS
Otherunder Preferred Stock Dividend,2021-03-31 00:00:00,,CYIENTDLM.NS
Net Income,2021-03-31 00:00:00,,CYIENTDLM.NS
Net Income Including Noncontrolling Interests,2021-03-31 00:00:00,,CYIENTDLM.NS
Net Income Continuous Operations,2021-03-31 00:00:00,,CYIENTDLM.NS
Tax Provision,2021-03-31 00:00:00,,CYIENTDLM.NS
Pretax Income,2021-03-31 00:00:00,,CYIENTDLM.NS
Other Non Operating Income Expenses,2021-03-31 00:00:00,,CYIENTDLM.NS
Special Income Charges,2021-03-31 00:00:00,0.0,CYIENTDLM.NS
Other Special Charges,2021-03-31 00:00:00,,CYIENTDLM.NS
Write Off,2021-03-31 00:00:00,0.0,CYIENTDLM.NS
Net Non Operating Interest Income Expense,2021-03-31 00:00:00,,CYIENTDLM.NS
Total Other Finance Cost,2021-03-31 00:00:00,19230000.0,CYIENTDLM.NS
Interest Expense Non Operating,2021-03-31 00:00:00,,CYIENTDLM.NS
Interest Income Non Operating,2021-03-31 00:00:00,17590000.0,CYIENTDLM.NS
Operating Income,2021-03-31 00:00:00,,CYIENTDLM.NS
Operating Expense,2021-03-31 00:00:00,,CYIENTDLM.NS
Other Operating Expenses,2021-03-31 00:00:00,,CYIENTDLM.NS
Depreciation And Amortization In Income Statement,2021-03-31 00:00:00,,CYIENTDLM.NS
Amortization,2021-03-31 00:00:00,4310000.0,CYIENTDLM.NS
Depreciation Income Statement,2021-03-31 00:00:00,,CYIENTDLM.NS
Research And Development,2021-03-31 00:00:00,1140000.0,CYIENTDLM.NS
Selling General And Administration,2021-03-31 00:00:00,211870000.0,CYIENTDLM.NS
Selling And Marketing Expense,2021-03-31 00:00:00,163830000.0,CYIENTDLM.NS
General And Administrative Expense,2021-03-31 00:00:00,48040000.0,CYIENTDLM.NS
Gross Profit,2021-03-31 00:00:00,,CYIENTDLM.NS
Cost Of Revenue,2021-03-31 00:00:00,,CYIENTDLM.NS
Total Revenue,2021-03-31 00:00:00,,CYIENTDLM.NS
Operating Revenue,2021-03-31 00:00:00,,CYIENTDLM.NS
